Fig. 2
From: Anti-lymphangiogenesis for boosting drug accumulation in tumors
Anti-lymphangiogenesis activity of anlotinib and SAR131675 both in vitro and in vivo. a–c Anlotinib inhibited the proliferation (a), migration (b), and tubule network formation (c) of hLECs (n = 4). Scale bar, 200 μm in (b) and 1000 μm in (c). d–f SAR131675 inhibited the proliferation (d), migration (e), and tubule network formation (f) of hLECs (n = 4). Scale bar, 200 μm in (e) and 1000 μm in (f). g Quantification of the recovered area by hLECs migration as shown in (b) (n = 3). h Quantification of the recovered area by hLECs migration as shown in and (e) (n = 3). i Quantification of tube lengths as shown in (c) (n = 3). j Quantification of tube lengths as shown in (f) (n = 3). k Immunohistochemistry staining for LVs (LYVE-1, brown) in 4T1 tumor sections from mice treated with saline, anlotinib or SAR131675. Scale bar, 40 μm. l Quantification of tumor LV density (n = 9; images were from three mice per group). m Typical images of inguinal LNs from different groups. Scale bar, 0.5 cm. The data are presented as the mean ± s.d. *p < 0.05; **p < 0.01; ***p < 0.001
